Neuraxpharm Group, a Spain-based specialty pharmaceutical company focused on the treatment of central nervous system (CNS) disorders, announced on Monday the launch of a new affiliate, Neuraxpharm Australia, led by newly appointed head of Commercial, Avendran Naidu, as the company continues to expand globally.

The launch of Neuraxpharm Australia follows the opening last year of Neuraxpharm Middle East and the establishment of affiliates in Brazil and Mexico in 2023. Based in Sydney, Neuraxpharm Australia will market the company's CNS products across Australia.

Neuraxpharm Australia will commercialise the prescription brands Nuvigil (armodafinil) and Modavigil (modafinil), both indicated for the treatment of Excessive Daytime Sleepiness (EDS) in adults with narcolepsy, which were acquired by Neuraxpharm in December 2024.

The Australian affiliate will also bring to market BRIUMVI (ublituximab) for the treatment of adult patients with relapsing-remitting multiple sclerosis (RRMS) after receiving approval from Australia's Therapeutic Goods Administration (TGA) in June 2025. Following a positive recommendation by the Pharmaceutical Benefits Advisory Committee (PBAC) at its May 2025 meeting, Neuraxpharm says that it is now working to ensure eligible Australian patients can access BRIUMVI as soon as possible.

Ublituximab, developed by TG Therapeutics and licensed by Neuraxpharm ex-US, is a novel anti-CD20 monoclonal antibody approved in the United States, the European Union, the UK and Switzerland for the treatment of adult patients with RRMS that can be administered in a one-hour infusion, twice a year, following the starting dose. Additional CNS treatments from Neuraxpharm's portfolio are expected to follow.